Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT03704688
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
- KRAS Gene Mutation
- Non Small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Trametinib 0.5 mg — DRUG0.5mg PO q daily
- Trametinib 1 MG — DRUG1.0 mg PO q daily
- Trametinib 1.5 MG — DRUG1.5mg PO q daily
- Trametinib 2 mg — DRUG2 mg PO q daily
- Ponatinib 15 MG — DRUG15mg PO q daily
- Ponatinib 30 MG — DRUG30mg PO q daily
Study Details
The purpose of this study is to evaluate the safety of the combination of ponatinib and trametinib as well as the most appropriate dosages of the combination.
Key Dates
- Start date
- Oct 9, 2018
- Status verified
- Feb 2022
- Primary completion
- Feb 4, 2022
- Completion
- Feb 4, 2022
Study Design
- Enrollment
- 12 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Phase I: Dose Level -3Trametinib 0.5mg PO q daily Ponatinib 15mg PO q daily
- Experimental: Phase I: Dose Level -2Trametinib 1.0 mg PO q daily Ponatinib 15mg PO q daily
- Experimental: Phase I: Dose Level -1Trametinib 1.5 mg PO q daily 15mg PO q daily
- Experimental: Phase I: Dose Level 1Trametinib 2 mg PO q daily Ponatinib 15mg PO q daily
- Experimental: Phase I: Dose Level 2Trametinib 2 mg PO q daily Ponatinib 30mg PO q daily
- Experimental: Phase IIMaximum tolerated dose as established in Phase I portion
Primary Outcome Measure
Maximum Tolerated Dose of Ponatinib, Phase I [ Time Frame: maximum of 18 months ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | - |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | - |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | - |
| Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity) | Commack | New York | 11725 | - |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | 10604 | - |
| Memorial Sloan - Kettering Cancer Center | New York | New York | 10021 | - |
| Memorial Sloan Kettering Nassau (Limited protocol activity) | Uniondale | New York | 11553 | - |
Find similar trials in Basking Ridge, NJ
By condition
By specialty
By research site
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity)· Commack, NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan - Kettering Cancer Center· New York, NY
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of DiseasePHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · San Carlos, California
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067PHASE1/PHASE2 · Recruiting · Simcha IL-18, Inc. · Scottsdale, Arizona
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)PHASE3 · Recruiting · AbbVie · Birmingham, Alabama